OBSERVATIONS ON XINGANBAO THERAPY OF LIVER FIBROSIS CAUSED BY ADVANCED SCHISTOSOMIASIS / 中国血吸虫病防治杂志

106 patients with liver fibrosis, 58 men (54.72%) and 48 women (45.28%), were treated with Xinganbao. All of these cases were diagnosed as portal hypertension of advanced schistosomiasis. The drug was given in a daily dose of 2.25g (250mg/capsule) 3 times a day for a succession of 2 months.The result of our study suggests that Xinganbao therapy can relieve and/or eliminate the clinical symptoms of advanced schistosomiasis with liver function recovered, serum albumin raised, ?-globulin decreased, immune function adjusted and caliber of portal and spleen vein much diminished. The total rate of efficacy was 89.62%, of which, 14.15% (15 cases) markedly improved while 75.47% (80 cases) moderately.